Hormone replacement therapy and endometrial cancer;Terapia de reposição hormonal e o câncer do endométrio

Cadernos de Saude Publica

Volumn 23, Issue 11, 2007, Pages 2613-2622

  De Araújo Jr , Naidilton Lantyer Cordeiro ^a   Athanazio, Daniel Abensur ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Endometrial neoplasms; Hormone replacement therapy; Women's health

Indexed keywords

EID: 36148986490     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/s0102-311x2007001100009     Document Type: Article

References (25)

1. Amant F, Moerman P, Neven P, Timmerman D, van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366:491-505.
2. Viana LC, Martins M, Geber S. Climatério. In: Alves J, organizador. Ginecologia. Rio de Janeiro: Medsi Editora; 1998. p. 504-8.
3. Federação Brasileira das Associações de Ginecologia e Obstetrícia. Tratado de ginecologia. Rio de Janeiro: Editora Revinter; 2001.
4. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293:1167-70.
5. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293:1164-7.
6. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365:1543-51.
7. Horwitz RI, Feinstein AR. Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 1978; 299:1089-94.
8. Case-control studies of estrogens and endometrial cancer. N Engl J Med 1979; 300:495-7.
9. Jick H, Watkins RN, Hunter JR, Dinan BJ, Madsen S, Rothman KJ, et al. Replacement estrogens and endometrial cancer. N Engl J Med 1979; 300:218-22.
10. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein LB, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985; 313:969-72.
11. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 1980; 302:551-4.
12. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298:147-51.
13. Voigt LF, Weiss NS, Chu J, Dailing JR, McKnight B, van Belle G, et al. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338:274-7.
14. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996; 275:370-5.
15. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994; 170(5 Pt 1):1213-23.
16. Comerci Jr. JT, Fields AL, Runowicz CD, Goldberg GL. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer. Gynecol Oncol 1997; 64:425-30.
17. Cushing KL, Weiss NS, Voigt LF, McKnight B, Beresford SA. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol 1998; 91:35-9.
18. Ziel HK, Finkle WD, Greenland S. Decline in incidence of endometrial cancer following increase in prescriptions for opposed conjugated estrogens in a prepaid health plan. Gynecol Oncol 1998; 68:253-5.
19. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Koopenberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33.
20. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-13.
21. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360:942-4.
22. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350:1047-59.
23. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003; 289:3254-63.
24. Fernandes CE. Consenso sobre a terapêutica hormonal na menopausa: controvérsias da terapêutica hormonal (TH) na mulher climatérica. São Paulo: Editora Medcomm; 2004.
25. Fernandes CE, Baracat EC, Lima GR. Manual do climatério. São Paulo: Editora Ponto; 2004.